Syndax Pharmaceuticals Inc
SNDX Nasdaq
SEC CIK 1395937
Follow Syndax Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$83.3M
+81.6% vs same quarter last year
Net income
−$49.4M
+18.6% vs same quarter last year
EPS, diluted
−$0.55
+21.4% vs same quarter last year
Operating cash flow
−$27.3M
+61.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $172.4M | −$285.4M |
| FY24 | $23.7M | −$318.8M |
| FY23 | $0 | −$209.4M |
| FY22 | $0 | −$149.3M |
| FY21 | $139.7M | $24.9M |
| FY20 | $1.5M | −$73.2M |
| FY19 | $1.5M | −$56M |
| FY18 | $1.5M | −$74M |
| FY17 | $2.1M | −$60.8M |
| FY16 | $1.2M | −$44.5M |
| FY15 | $627K | −$24.1M |
| FY14 | - | −$19.8M |
| FY13 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −158.4% | −165.6% |
| FY24 | −1434.4% | −1346.3% |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | 18.8% | 17.8% |
| FY20 | −4708.2% | −4822.5% |
| FY19 | −3792.9% | −3694.6% |
| FY18 | −5001.7% | −4875.5% |
| FY17 | −2939% | −2884.3% |
| FY16 | −3587.4% | −3645.2% |
| FY15 | −3271.6% | −3846.7% |
| FY14 | - | - |
| FY13 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$323.2M |
| FY24 | −$274.9M |
| FY23 | −$160.6M |
| FY22 | −$133.7M |
| FY21 | $29M |
| FY20 | −$71.3M |
| FY19 | - |
| FY18 | −$68.7M |
| FY17 | −$47.5M |
| FY16 | −$35.4M |
| FY15 | −$2.5M |
| FY14 | −$14.4M |
| FY13 | - |
- Syndax Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Syndax Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −165.6% | −30.6% |
| FY24 | −1346.3% | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | 17.8% | −71.8% |
| FY20 | −4822.5% | −62.2% |
| FY19 | −3694.6% | −46.2% |
| FY18 | −4875.5% | −49.6% |
| FY17 | −2884.3% | −45.9% |
| FY16 | −3645.2% | −36% |
| FY15 | −3846.7% | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |